A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Name: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
Published: 2024
License: Public Domain

Sarepta Therapeutics, Inc. · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

duchenne-muscular-dystrophy pediatric

duchenne muscular dystrophy, gene-delivery, dmd, ambulatory, pediatric, duchenne, pre-existing antibodies, raavrh74 antibody, seropositive, seropositivity, titer, interventional

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Related documents